
- Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth.
- LLY has strong technical momentum and is trading at new all-time highs.
- Shares are up 43% over the past year.
- Analyst sentiment is overwhelmingly positive, with most major firms rating LLY a “Buy.”